GOUT DISEASE TREATMENT MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Increased Generic Drug Availability

The expiry of patents and introduction of generic medicines have provided more treatment choices and lowered drug costs for gout patients. Several pivotal gout drugs including allopurinol and colchicine have gone off-patent, allowing many pharmaceutical companies to manufacture and market affordable generic equivalents. This has expanded treatment access in both developed and developing healthcare markets. Particularly in developing Asian and Latin American countries, cheaper generics have helped to address the growing needs of their population burdened by gout. The good cost-benefit ratio and increasing familiarity with generic medicines have prompted many physicians to prescribe lower-cost generic therapy as the first line of treatment. With rising global gout rates due to lifestyle changes, the extensive availability of more affordable generic options has facilitated widespread treatment uptake to better manage this increasingly common form of arthritis. Generic drugs have played a catalytic role in boosting uptake of prescription therapies.